United Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
United Therapeutics has a total shareholder equity of $5.3B and total debt of $600.0M, which brings its debt-to-equity ratio to 11.2%. Its total assets and total liabilities are $6.5B and $1.2B respectively. United Therapeutics's EBIT is $1.3B making its interest coverage ratio -9.8. It has cash and short-term investments of $2.7B.
Key information
11.2%
Debt to equity ratio
US$600.00m
Debt
| Interest coverage ratio | -9.8x |
| Cash | US$2.71b |
| Equity | US$5.34b |
| Total liabilities | US$1.16b |
| Total assets | US$6.50b |
Recent financial health updates
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20Recent updates
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17United Therapeutics reaches all-time high; shares up 15% YTD
Jul 06Why Hold United Therapeutics After Shares Doubled?
Jun 08With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting
May 06Financial Position Analysis
Short Term Liabilities: UTHR's short term assets ($3.2B) exceed its short term liabilities ($860.6M).
Long Term Liabilities: UTHR's short term assets ($3.2B) exceed its long term liabilities ($296.5M).
Debt to Equity History and Analysis
Debt Level: UTHR has more cash than its total debt.
Reducing Debt: UTHR's debt to equity ratio has reduced from 45.3% to 11.2% over the past 5 years.
Debt Coverage: UTHR's debt is well covered by operating cash flow (163.3%).
Interest Coverage: UTHR earns more interest than it pays, so coverage of interest payments is not a concern.